As of 2025-05-19, the EV/EBITDA ratio of Chiome Bioscience Inc (4583.T) is -7.98. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 4583.T's latest enterprise value is 8,112.64 mil JPY. 4583.T's TTM EBITDA according to its financial statements is -1,016.31 mil JPY. Dividing these 2 quantities gives us the above 4583.T EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.1x - 7.8x | 6.4x |
| Forward P/E multiples | 5.4x - 7.5x | 6.6x |
| Fair Price | (54.99) - (86.78) | (71.56) |
| Upside | -137.7% - -159.4% | -149.0% |
| Date | EV/EBITDA |
| 2025-02-14 | -12.32 |
| 2025-02-13 | -15.12 |
| 2025-02-12 | -14.65 |
| 2025-02-10 | -14.92 |
| 2025-02-07 | -15.45 |
| 2025-02-06 | -14.32 |
| 2025-02-05 | -14.78 |
| 2025-02-04 | -14.85 |
| 2025-02-03 | -14.78 |
| 2025-01-31 | -14.85 |
| 2025-01-30 | -15.25 |
| 2025-01-29 | -14.05 |
| 2025-01-28 | -14.25 |
| 2025-01-27 | -13.72 |
| 2025-01-24 | -13.38 |
| 2025-01-23 | -12.38 |
| 2025-01-22 | -12.32 |
| 2025-01-21 | -12.72 |
| 2025-01-20 | -12.72 |
| 2025-01-17 | -13.72 |
| 2025-01-16 | -14.25 |
| 2025-01-15 | -16.25 |
| 2025-01-14 | -16.85 |
| 2025-01-10 | -14.92 |
| 2025-01-09 | -15.52 |
| 2025-01-08 | -14.92 |
| 2025-01-07 | -15.78 |
| 2025-01-06 | -16.18 |
| 2024-12-30 | -16.18 |
| 2024-12-27 | -15.92 |
| 2024-12-26 | -15.52 |
| 2024-12-25 | -15.25 |
| 2024-12-24 | -14.45 |
| 2024-12-23 | -14.58 |
| 2024-12-20 | -13.92 |
| 2024-12-19 | -16.45 |
| 2024-12-18 | -16.98 |
| 2024-12-17 | -16.38 |
| 2024-12-16 | -15.05 |
| 2024-12-13 | -13.85 |
| 2024-12-12 | -13.45 |
| 2024-12-11 | -11.65 |
| 2024-12-10 | -13.05 |
| 2024-12-09 | -13.38 |
| 2024-12-06 | -11.78 |
| 2024-12-05 | -11.18 |
| 2024-12-04 | -10.18 |
| 2024-12-03 | -10.25 |
| 2024-12-02 | -10.78 |
| 2024-11-29 | -12.05 |